Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-411.19%
operating margin TTM
-443.54%
revenue TTM
1.46 Million
revenue per share TTM
0.02$
valuation ratios | |
|---|---|
| pe ratio | -2.63 |
| peg ratio | 0.06 |
| price to book ratio | 7.19 |
| price to sales ratio | 10.85 |
| enterprise value multiple | -2.66 |
| price fair value | 7.19 |
profitability ratios | |
|---|---|
| gross profit margin | 94.66% |
| operating profit margin | -443.54% |
| pretax profit margin | -411.08% |
| net profit margin | -411.19% |
| return on assets | -45.14% |
| return on equity | -141.95% |
| return on capital employed | -57.66% |
liquidity ratios | |
|---|---|
| current ratio | 6.15 |
| quick ratio | 6.14 |
| cash ratio | 0.39 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 80.36 |
| operating cycle | 149.90 |
| days of payables outstanding | 671.38 |
| cash conversion cycle | -521.48 |
| receivables turnover | 5.25 |
| payables turnover | 0.54 |
| inventory turnover | 4.54 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.04 |
| debt equity ratio | 0.22 |
| long term debt to capitalization | 0.08 |
| total debt to capitalization | 0.18 |
| interest coverage | -296.13 |
| cash flow to debt ratio | -3.21 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.95 |
| cash per share | 6.55 |
| operating cash flow per share | -0.88 |
| free cash flow operating cash flow ratio | 1.08 |
| cash flow coverage ratios | -3.21 |
| short term coverage ratios | -60.78 |
| capital expenditure coverage ratio | -12.05 |
Frequently Asked Questions
When was the last time Kura Oncology, Inc. (NASDAQ:KURA) reported earnings?
Kura Oncology, Inc. (KURA) published its most recent earnings results on 12-05-2026.
What is Kura Oncology, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Kura Oncology, Inc. (NASDAQ:KURA)'s trailing twelve months ROE is -141.95%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Kura Oncology, Inc. (KURA) currently has a ROA of -45.14%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did KURA's net profit margin stand at?
KURA reported a profit margin of -411.19% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is KURA's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 6.15 in the most recent quarter. The quick ratio stood at 6.14, with a Debt/Eq ratio of 0.22.